The Cholangiocarcinoma Foundation Announces Executive Director

Posted by on Feb 5, 2013 in Uncategorized | 0 comments

We would like  welcome Kim Crittenden, the new Executive Director for the Cholangiocarcinoma Foundation. Kim brings more than 20 years of experience as an administrator, program manager, volunteer and board member serving the non-profit sector. She will help direct the foundation for the coming years as it continues to grow in its support of those who are suffering with bile duct cancer, as well as lead the effort to fund research for a cure.
In her professional life she specializes in small, start-up, and growing non-profit organizations with experience in non-profit administration, program development and evaluation; volunteer recruitment and management; conference and special event planning; as well as grant writing and fundraising. She earned dual bachelor degrees in Sociology and Behavioral Science and Health from the University of Utah. Currently, she is finishing a Masters of Public Administration with an Executive Cohort at the University of Utah. She resides in the beautiful Heber Valley east of Salt Lake City with her son and cocker spaniel.
Welcome Kim. We look forward to a great 2013.
Read More

LIFe Recipient Suebong Tanasanvimon,MD of Thailand to Present Research

Posted by on Feb 1, 2013 in Uncategorized | 0 comments

Touching base with LIFe recipient Suebpong Tanasanvimon, MD


The 2011 Long-term International Fellowship (LIFe) recipient Dr. Tanasanvimon, MD, of King Chulalongkorn Memorial Hospital, in Bangkok, Thailand  will be presenting his research on Cholangiocarcinoma at the Gastrointestinal Cancers Symposium on January 25, 2013.

The LIFe fellowship was funded by the Cholangiocarcinoma foundation and enables early-career oncologists from low- and middle-income countries to experience valuable training and experience at a U.S. or Canadian institution, which they can later use to facilitate change in cancer care in their home country.

Follow the link below to read more on the interview with Dr. Tanasanvimon and the upcoming presentation of his research findings.



Read More

February is Cholangiocarcinoma Awareness Month

Posted by on Feb 1, 2013 in Uncategorized | 0 comments

February is cholangiocarcinoma awareness month, and The Cholangiocarcnoma Foundation will be leading numerous events in February to help raise awareness of this rare cancer. Events includefundraising for 2013 research grants, awareness drives on Facebook and Twitter, spotlight webinars on research efforts, and much more.

 “February gives our community a dedicated month-long opportunity to focus their energy to educate the general public about cholangiocarcinoma (bile duct cancer) and the challenges associated with diagnosis, living with this cancer and finding a cure,” said foundation president, Stacie Lindsey. She added, “Similar to last year’s effort, we’ll be offering engaging and informative activities based on our mission of Collaboration, Understanding, Research and Education to assist with directing our efforts.” To participate or learn more visit the foundation’s web site at: http://www.cholangiocarcinoma.org

Read More

Foundation Awards $184,202 in Grants and Project Funding in 2012

Posted by on Jan 31, 2013 in Uncategorized | 0 comments

The Cholangiocarcinoma Foundation awarded $184,202 in Grants and Project Funding in 2012.   A $40,000 Grant was awarded to the UCSF Hepatobiliary Tissue Bank(CC#124512) which will support the advancing translational Science in Cancers of Biliary Tract through Biorepository of Human Tumor and Blood Specimens.  The goal of the HBTB is to advance our understanding of this rare and under-studied tumor type.  The immediate goal of the HBTB is to collect high quality frozen cholangiocarcinoma specimens along with paired normal tissue (blood or normal liver) to support the opening of a cholangiocarcinoma cohort with the National Cancer Institute’s the Cancer Genome Atlas (TCGA). Another $40,000 was awarded for Cell Lines and Novel Antibodies at Massachusetts General Hospital.  The support will test a novel immunotherapeutic strategy which targets not only differentiated cholangiocarcinoma cells, but all cholangiocarcinoma stem cells.  An additional $44,202 was given to the Mayo Clinic for Hepatobiliary Neoplasia Registry and Biorepository.  The overall goal is to support the collection of clinical information and samples of blood and tissue from patients with  hepatobiliary neoplasia in an IRB approved International Hepatobiliary Neoplasia Registry and Biorepository.  Finally, The American Society of Clinical Oncology was awarded $60,000 for its Young Investigator Award.  This grant is intended to raise awareness and trigger progress against cholangiocarcinoma, while providing critical early funding for physician-scientists at the beginning of their careers in the field.  Providing early career grants helps encourage investigators to focus their career on bile duct cancer.

Read More

Oxford University-UK, interested in collaborating with The Cholangiocarcinoma Foundation

Posted by on Nov 30, 2012 in Uncategorized | 1 comment

Dr. Said Almamari from Oxford University in the UK is very interested in collaborating with the Cholangiocarcinoma Foundation. He is currently doing research on Primary Sclerosing Cholangitis (PSC) and Cholangiocarcinoma (CC). Upon the completion of his Study he will return to Yemen, where there are many cases being untreated.


Read More

Patient Advocacy at the AASLD-The Liver Meeting

Posted by on Nov 30, 2012 in Uncategorized | 0 comments

Barbara DuPont, our very own Advocacy Volunteer represented The Cholangiocarcinoma Foundation at the American Association for the Study of Liver Diseases, AASLD – The Liver Meeting.  The meeting was held in Boston, November 10 – 12.  Saturday, Nov. 10th which was also the 5 year anniversary of the loss of Barbara’s love  Jacques to Cholangicarcinoma – being at this convention was just where she needed to be on this day.

This was the first time that The Cholangiocarcinoma Foundation was present at the AASLD, American Association for the Study of Liver Diseases . Their were approximately 10,000 attendees. The Liver Meeting is the premier annual US conference on hepatology, covering all aspects of liver disease including viral hepatitis, fatty liver, hepatocellular carcinoma, and liver transplantation. Barbara was able to speak with physicians, surgeons, fellows, researchers, scientists etc. from all over the world AND handed out over 250 brochures and ran out of bracelets (180) on the last day.

The booth was located on Foundation Row, which was an excellent place to be. It was set up in a large hallway that led into the main exhibit hall, everyone had to pass by us to go to the exhibit hall. There were 11 other foundations , including several international foundations. We were the only Patient Advocacy Foundation in attendance.

Numerous attendees from Greece, Egypt, Costa Rica, United Kingdom, Thailand, Cairo, and Toronto were very interested in knowing about the foundation, as they are seeing a rise in incidence in their country. One physician from Costa Rica said that she alone has 6 cases this year. She was alarmed because her patients are young and they have a small population. She also knows of physicians in other towns in Costa Rica who are also seeing patients. Many had heard about The Cholangiocarcinoma Foundation and many had not. Barbara was able to show many attendees the site with the use of her iPad.  Everyone was very impressed with the wealth of information it contained.  Many people expressed their thanks for the immense efforts of the foundation in raising awareness. It is through this awareness that research, the ability to detect at an early stage, and the improvement of the treatment and care of people living with this cancer will receive, as well as the hope for a cure.

This was a successful venue for the Foundation. Plans to attend next year will be strongly considered.  There was a true sense of increased attention and effort by the scientific and medical communty to further research and improve the options that are available to treat Cholangicarcinoma.


Read More